Editor’s note: This is a developing news story. Please check back soon for updates.
Seonix Bio launched SightScore, a polygenic risk score testing service for primary open-angle glaucoma, in the United States, according to a press release.
SightScore contributes to a more personalized treatment approach by distinguishing between patients who may be at higher or lower risk for glaucoma. The saliva test evaluates a patient’s genetic variants to estimate the risk for developing glaucoma or the risk for progression in those who already have the disease.
Clinicians can prioritize and